Cargando…

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jørgensen, Charlotte LT, Ejlertsen, Bent, Bjerre, Karsten D, Balslev, Eva, Nielsen, Dorte L, Nielsen, Kirsten V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840598/ https://www.ncbi.nlm.nih.gov/pubmed/24215511 http://dx.doi.org/10.1186/1471-2407-13-541

Ejemplares similares

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
por: Jørgensen, Charlotte Levin Tykjær, et al.
Publicado: (2014)

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Stovgaard, Elisabeth S, et al.
Publicado: (2021)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Structural study of the Fox-1 RRM protein hydration reveals a role for key water molecules in RRM-RNA recognition
por: Krepl, Miroslav, et al.
Publicado: (2017)

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
por: Cheng, Bisheng, et al.
Publicado: (2023)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells
por: Kato, Tomotaka, et al.
Publicado: (2021)

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2023)

Independent prognostic implications of RRM2 in lung adenocarcinoma
por: Ma, Chao, et al.
Publicado: (2020)

Zinc Binds to RRM2 Peptide of TDP-43
por: Golovin, Andrey V., et al.
Publicado: (2020)

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
por: Zhang, Keqiang, et al.
Publicado: (2009)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

SLIRP stabilizes LRPPRC via an RRM–PPR protein interface
por: Spåhr, Henrik, et al.
Publicado: (2016)

Structural basis of IMP3 RRM12 recognition of RNA
por: Jia, Min, et al.
Publicado: (2018)

TIA-1 RRM23 binding and recognition of target oligonucleotides
por: Waris, Saboora, et al.
Publicado: (2017)

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer
por: Zhou, Zijian, et al.
Publicado: (2022)

Deciphering the RRM-RNA recognition code: A computational analysis
por: Roca-Martínez, Joel, et al.
Publicado: (2023)

A missense mutation in RRM1 contributes to animal tameness
por: Dou, Mingle, et al.
Publicado: (2023)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer
por: Chen, Wei-xian, et al.
Publicado: (2019)

The structure and selectivity of the SR protein SRSF2 RRM domain with RNA
por: Phelan, Marie M., et al.
Publicado: (2012)

RRM2 is a potential prognostic biomarker with functional significance in glioma
por: Sun, Hongzhi, et al.
Publicado: (2019)

ATP binds and inhibits the neurodegeneration-associated fibrillization of the FUS RRM domain
por: Kang, Jian, et al.
Publicado: (2019)

Histone chaperones and the Rrm3p helicase regulate flocculation in S. cerevisiae
por: Rowlands, Hollie, et al.
Publicado: (2019)

Identification and Characterization of an RRM-Containing, RNA Binding Protein in Acinetobacter baumannii
por: Ciani, Caterina, et al.
Publicado: (2022)

CpG oligonucleotides bind TLR9 and RRM-Containing proteins in Atlantic Salmon (Salmo salar)
por: Iliev, Dimitar B, et al.
Publicado: (2013)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance
por: Abdel-Rahman, Manar Ahmed, et al.
Publicado: (2022)

High RRM2 expression has poor prognosis in specific types of breast cancer
por: Shi, Shen-chao, et al.
Publicado: (2022)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p3lofff0fh81jo48et2ecps1qp